ProCE Banner Activity

BRUIN: First-in-Human Phase I Trial Investigating Non-Covalent BTK Inhibitor LOXO-305 in Pretreated B-Cell Malignancies

Slideset Download
Conference Coverage
LOXO-305, a non-covalent BTK inhibitor, demonstrated preliminary antitumor activity and manageable safety in pretreated B-cell malignancies including those resistant to previous BTKi therapy.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company